The Clinical Research Institute of Mar del Plata (IIC) was selected by the Military Hospital Research Center to be part of an ambitious overall study to find an effective treatment or vaccine against Respiratory Syncytial Virus (RSV), responsible for the bronchiolitis, pneumonia, or severe respiratory conditions.
The Institute is already part of a Phase 3 study to evaluate the efficacy and safety of an RSV vaccine in people over 60 years of age, for which volunteers and volunteers are required.
The Dr. Gonzalo Pérez Marcin charge of the study, explained to LA CAPITAL that “RSV is the main responsible for bronchiolitis, pneumonia or serious respiratory conditions for people over 60 years of age such as: asthma, COPD or congestive heart failure. It is also the leading cause of hospitalization in children under 1 year of age.”
It is the third most common virus after the flu and Covid in older adults. It is spread by coughing and sneezing and is characterized by causing infections in the lungs and airways of those who contract it.
“We are talking about the same virus that, for example, produces bronchiolitis in infants. It is the main disease of infants during winter throughout the world. And it is the respiratory virus that has the highest infant mortality in the world. In people over 60 years of age, it is known that it can cause a serious lung disease, like the level of the flu, of influenza, which is generally not diagnosed or certain because there is no vaccine or treatment. It is known that in high-risk people, with respiratory, cardiac or diabetes diseases, among others, it can generate high mortality “extended Dr. Pérez Marc.
The study, in which countries such as the United States, Canada, Finland, Japan, South Africa, the Netherlands, among others, participate, is the previous step to a triple vaccine immunization against coronavirus, influenza and bronchiolitis.
“To date there are no effective vaccines for this virus. So this trial is very important, which is carried out with people over 60 years of age in different countries, with volunteers who can already begin to enroll,” said the person in charge of the study.
Headquarters of the Clinical Research Institute of Mar del Plata.
–
Mar del Plata, through the Clinical Research Institute, is part of the trial and those over 60 who are interested can register via the web at www.vacuna60.com or obtain more information through the cell phone 223-5905044.
“We will be developing the study during June and July”, said Dr. Pérez Marc and specified that the volunteers “They will be given a Pfizer vaccine, a single dose, and then they will be followed up for three years.”
Research studies are the basis for the development of new drugs and vaccines. They are possible thanks to the contribution of scientists, doctors, volunteers and regulatory agencies. Research data brings together scientific evidence that demonstrates safety, efficacy, and extends its benefits to millions of people.
Regarding the results obtained so far, the doctor assured that “phase 1 and 2 studies were very good and progress is needed”, and then highlighted: “We are testing a vaccine against one of the main respiratory viral diseases that cause the most damage in the world every year. For the first time we could have protection against this disease.”
The requirement to access the research is to be over 60 years old, with or without chronic pathologies, whether or not they are vaccinated against Covid-19 and the flu. Once registered, they will be contacted by the IIC. Those who wish to participate must register on the website www.vacuna60.com and complete the short form that appears there.
–
